Danaher Corp
DHRQ3 2025(DHR Q2 FY2025)Estimated1% AI
AI Revenue %
1%
AI Fair Value
$823.3M
AI Revenue (Q)
$115.4M
Total Revenue (Q)
$11.5B
Source: SEC EDGAR 10-Q Filing
View 10-Q on SEC.govAnalysis
Q2 FY2025 (three-month period ended June 27, 2025). Total sales $5,936M. Segments: Biotechnology $1,850M, Life Sciences $1,777M, Diagnostics $2,309M. Life Sciences took a $432M impairment charge this quarter. No AI revenue disclosure. No AI-specific mentions beyond risk factor language. Conservative 1% for embedded instrument algorithms. Math: ~$59M estimated / $5,936M total = ~1.0%.
Analyzed by claude-opus-4-6
Quoted Figures
Sales $5,936 [three-month period ended June 27, 2025]
10-Q Q2 FY2025, Consolidated Condensed Statements of Earnings
Biotechnology $1,850; Life Sciences $1,777; Diagnostics $2,309 [three-month period ended June 27, 2025]
10-Q Q2 FY2025, Note 5 Segment Information
AI Products Identified (Ring 1)
Embedded instrument algorithms (digital pathology, flow cytometry, clinical chemistry)
AI-Enabled Items (Ring 2 — Not Counted)
These items use AI but are not counted in the AI revenue estimate because they primarily serve non-AI functions.
Biotechnology consumables/bioprocessingLife Sciences instrumentsDiagnostics instruments
Confidence Tier
EstimatedNo direct AI revenue disclosure — estimated from product mix